CRISPR edits to stimulate healthier hemoglobin could prove sickle cell cure

Besides being a benign genetic condition, the hereditary persistence of fetal hemoglobin could, with some help from CRISPR, lead to a new treatment for common blood disorders, such as sickle cell anemia and beta-thalassemia.

Sickle cell and beta-thalassemia are caused by genetic mutations in a component called “beta” that is present only in adult hemoglobin, said St. Jude Children’s Research Hospital, which led the research, in a statement. Individuals start showing symptoms after birth, as adult hemoglobin gradually replaces fetal hemoglobin.

Fetal hemoglobin does not have “beta” components and have “gamma” subunits instead, St. Jude said. And so, the genetic mutations that cause these disorders do not affect fetal hemoglobin. It has long been known that blocking the “gamma-to-beta” switching of hemoglobin components can increase the levels of fetal hemoglobin in adults, thus alleviating sickle cell and beta-thalassemia symptoms, according to the statement.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

“Our work has identified a potential DNA target for genome editing-mediated therapy and offers proof-of-principle for a possible approach to treat sickle cell and beta-thalassemia,” said Dr. Mitchell Weiss, chair of St. Jude’s Department of Hematology, in the statement. The team “snipped” out the target using CRISPR, removing a short section of DNA that drives “gamma-to-beta” switching and resulting in “sustained” elevated levels of fetal hemoglobin in adult red blood cells, Weis said. They worked on blood cells isolated from patients with sickle cell and beta-thalassemia, and were able to generate red blood cells with enough fetal hemoglobin to be healthy, the statement said.

“Using genome editing to restore the hereditary persistence of fetal hemoglobin is an attractive possibility, because it can be achieved relatively easily using current technologies,” Weiss said.

While it’s an appealing possibility, the researchers caution there’s much refinement to be done before clinical trials can be considered. They want to perfect the gene-editing process to avoid off-target effects that could potentially be harmful.

- here's the statement
- read the study abstract

Related Articles:
Faster CRISPR in mice makes modeling human disease easier
CRISPR/Cas9 gene activation 'guide' could lead to new therapies
Fast-spreading CRISPR tech inspires new preclinical work on blood cancers

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.